about
KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A * 11 while diminishing avidity for HLA-CLoss of mismatched HLA in leukemia after stem-cell transplantation.Improving the safety of cell therapy with the TK-suicide geneDroplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.Use of TK-cells in haploidentical hematopoietic stem cell transplantation.Experts' considerations on HLA-haploidentical stem cell transplantation.NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation.Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome.High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory.Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia.Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation.Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation.T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients.Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Choosing the Alternative.Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.Haploidentical HSCT: a 15-year experience at San Raffaele.Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP.Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse.A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors.Allogeneic hematopoietic stem cell transplantation for neuromyelitis opticaSignificantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparitiesElderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs
P50
Q27657994-7A4B7879-1BDA-4FEE-A87A-86BB9300EFCCQ34018719-957D8151-B21A-4ED0-A6D2-E5F98602A483Q34477411-7FF2B6DF-C04F-43A5-838B-720876CD19A8Q37216267-505387F0-832A-498E-B769-659DFB87C6D0Q37488382-F3403406-D02B-4934-AA34-73E40985680AQ38037326-5909D683-389B-4D7B-9572-A73BA9A998A4Q38198728-27E16D1A-6E81-41B5-A212-DBC1CD682C31Q38699490-A18DA8C1-CA95-465F-803D-FBB068E6D831Q38936016-CFA0FF44-6B92-48FA-A943-BCAF5A0805A1Q40083763-D5388FD2-BA2D-43E3-B981-911FD1A0D8F9Q40639927-962A9D66-A20D-4D9D-915D-9396CCBB40D5Q40700663-D006DD94-EEA3-415B-BB6A-77787BF916E3Q40874040-E2569B01-906F-47A9-AD21-1BB303665594Q41206823-D852DC82-ABE3-4692-BE30-FC21DB1C014CQ41452544-715F8451-85DB-40CB-B711-A3A550D8087BQ41676842-A819A14A-2045-4177-BBD8-BF6E47306D4AQ42212281-60FADC87-EE26-4DF2-9331-A7556BA24912Q42378226-C1243A03-35B1-427D-9441-70C6E0D610F5Q44743006-4C59A4AF-59CD-40C1-9010-B038697BF342Q45172988-D7F7012F-BB48-4792-9E2D-AEC4AE9C0224Q45870209-B9600106-4054-4476-B4D7-3C73724E5E45Q45876839-D79F11CA-8AB3-4CD2-81C0-C63C0F8249B0Q45879182-5ACBDDA5-A41B-4680-963E-6ACCD963106FQ45879835-18581357-949E-430F-93E4-EEBC13C95FF5Q47554129-E97AE025-5BF5-4EBD-9E85-A084ED25AC7EQ47724804-5D5FCAB8-1A2D-4FC7-86E6-F78693DD8FABQ47847626-7980156F-08F6-41FF-832B-19F7DACCBC56Q47988768-9B7EA3A7-DF4F-4EEA-9E7B-8657B9F6D78AQ49217113-5FA4E20F-EB5B-4BB7-9E0C-A950567BC8ADQ49830211-9770E308-9DC1-4175-9573-E26C30DA6605Q49913447-7B0FDF76-4474-4854-AB0D-E74896ACCC1FQ50066002-7C7DCA96-8457-4A23-98D8-B727D5F78C0CQ50548477-AEE45EDD-EEF4-4BFA-A6EA-84A199CBAF90Q52718684-41F50816-2BED-4FCE-9B51-102EAF4BFCCFQ53257785-3F58B8D6-D37C-4380-A838-8D94044F415DQ54114521-8CE748BD-EEB4-4A27-89FF-4BB8C73ADEEEQ54534706-C8618648-02F4-4A45-8B3B-8C74B19D5823Q57267894-52B83402-CA61-49CC-B379-92B57D5B1C32Q85040932-C90FE1DA-C5A2-442C-B16E-2B9DD1D424BDQ87395160-0B10A118-D108-4AF0-B056-367EE09B6C5B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Luca Vago
@ast
Luca Vago
@en
Luca Vago
@es
Luca Vago
@sl
type
label
Luca Vago
@ast
Luca Vago
@en
Luca Vago
@es
Luca Vago
@sl
prefLabel
Luca Vago
@ast
Luca Vago
@en
Luca Vago
@es
Luca Vago
@sl
P106
P1153
56273709300
P21
P31
P496
0000-0003-4247-3175